- Home
- BKE vs RARE Comparison
BKE vs RARE Comparison
Compare BKE & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | RARE |
|---|---|---|
| Founded | 1948 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 1992 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BKE | RARE |
|---|---|---|
| Price | $47.12 | $24.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | $55.00 | ★ $73.11 |
| AVG Volume (30 Days) | 568.0K | ★ 2.9M |
| Earning Date | 03-13-2026 | 02-13-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | ★ 3.79 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $1,277,894,000.00 | $630,598,000.00 |
| Revenue This Year | $7.42 | $20.17 |
| Revenue Next Year | $2.75 | $19.10 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | 4.67 | ★ 20.63 |
| 52 Week Low | $33.12 | $18.41 |
| 52 Week High | $61.69 | $46.50 |
Technical Indicators
Market Signals| Indicator | BKE | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 26.51 | 42.60 |
| Support Level | $51.77 | $22.00 |
| Resistance Level | $49.49 | $25.00 |
| Average True Range (ATR) | 1.82 | 1.03 |
| MACD | -0.74 | 0.51 |
| Stochastic Oscillator | 0.05 | 74.67 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.